Literature DB >> 16223707

Polo-like kinase (Plk) 1 as a target for prostate cancer management.

Shannon Reagan-Shaw1, Nihal Ahmad.   

Abstract

Prostate cancer (PCa) is the most commonly occurring cancer in American men, next to skin cancer. Existing treatment options and surgical intervention are unable to effectively manage this cancer. Therefore, continuing efforts are ongoing to establish novel mechanism-based targets and strategies for its management. The serine/threonine kinases Polo-like kinase (Plk) 1 plays a key role in mitotic entry of proliferating cells and regulates many aspects of mitosis which are necessary for successful cytokinesis. Plk1 is over-expressed in many tumor types with aberrant elevation frequently constituting a prognostic indicator of poor disease outcome. This review discusses the studies which indicate that Plk1 could be an excellent target for the treatment as well as chemoprevention of prostate cancer. IUBMB Life, 57: 677-682, 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223707     DOI: 10.1080/15216540500305910

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  9 in total

Review 1.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

Review 2.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

Review 3.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

4.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Authors:  Justin P Dassie; Xiu-Ying Liu; Gregory S Thomas; Ryan M Whitaker; Kristina W Thiel; Katie R Stockdale; David K Meyerholz; Anton P McCaffrey; James O McNamara; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2009-08-23       Impact factor: 54.908

5.  The transcription factor YY1 is a substrate for Polo-like kinase 1 at the G2/M transition of the cell cycle.

Authors:  Raed Rizkallah; Karen E Alexander; Ari Kassardjian; Bernhard Lüscher; Myra M Hurt
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

6.  Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.

Authors:  Anna Tankiewicz-Kwedlo; Justyna Magdalena Hermanowicz; Tomasz Domaniewski; Krystyna Pawlak; Małgorzata Rusak; Anna Pryczynicz; Arkadiusz Surazynski; Tomasz Kaminski; Adam Kazberuk; Dariusz Pawlak
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

7.  Mitotic Kinases and p53 Signaling.

Authors:  Geun-Hyoung Ha; Eun-Kyoung Yim Breuer
Journal:  Biochem Res Int       Date:  2012-07-19

8.  The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.

Authors:  Hefei Li; Haibo Wang; Zhenqing Sun; Qiang Guo; Hongyun Shi; Youchao Jia
Journal:  Biosci Rep       Date:  2017-07-19       Impact factor: 3.840

Review 9.  Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.

Authors:  Monika Kressin; Daniela Fietz; Sven Becker; Klaus Strebhardt
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.